C—erbB-2在甲状腺良恶性疾病中的表达

The expression of C-erbB-2 in benign and malignant thyroid lesions

目的探讨C-erbB-2在甲状腺良恶性疾病中的表达及其临床意义。方法应用免疫组织化学sP法检测66例甲状腺手术切除标本的C-erbB-2。结果甲状腺良性疾病中C—erbB-2的阳性率为13．95％（6／43），甲状腺癌中C—erbB-2的阳性率为39．13％（9／23），两者差异有统计学意义（P〈0．025）。在甲状腺良恶性疾病中，C—erbB-2的阳性表达均与患者性别、年龄、肿瘤部位无关（P〉0．05），C—erbB-2的阳性表达与甲状腺癌肿瘤大小显著相关（P〈0．05）。C-erbB-2与甲状腺癌的淋巴结转移无显著相关性（P〉0．05）。结论C-erbB-2与甲状腺癌的发生及转化方面有一定关系。

Objective To study the clinical significance of C-erbB-2 expression in benign and malignant thyroid lesions. Methods The expressions of C-erbB-2 were detected by immunohistochemistry assays in 66 cases of thyroid lesions. Results The positive rates of C-erbB-2 expression was 13.95% （6/43） in benign thyroid diseases, 39.13% （9/23） in malignant thyroid diseases. There was significant difference between the expression of C-erbB-2 in malignant thyroid lesions and that in benign lesions（ P 〈 0. 025 ）. The analysis with corresponding clinical prognostic factors showed that the positive expression of C-erbB-2 in benign and malignant thyroid lesions had no correlation with sex, age, lymph nodes metastase and node position（ P 〉 0.05 ）. Expressions of C-erbB-2 had a significant positive correlation with tumor diameter （ P 〈 0. 05 ）. Conclusions C-erbB-2 expression is correlated with the carcinogenesis and development of thyroid carcinoma.